oncology

Value-based care takes over J.P. Morgan Healthcare Conference 2017Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.
Top challenges in cancer careCancer drug costs remain the most critical challenge in care, among other things.
Watch list 2017: Top therapeutic areas
Watch list 2017: Top therapeutic areasFind out about the latest treatment and drug pipeline developments
Is a urine-based test the future of cervical cancer screening?A Phase II study examines the efficacy of a urine-based test in screening for cervical cancer. Also, a study looks at whether cost is the reason why some patients do not adhere to breast cancer medications.
Family history, genetics play growing role in leukemia screeningInherited susceptibilities to leukemias are becoming better understood and have important implications for screening, prevention, genetic counseling, and treatment.
Gene therapy could be ‘ultimate solution’ for sickle cell diseaseInvestigational gene therapies might reduce the suffering and death caused by this genetic disease.
Top barriers to fully utilizing precision medicine biomarkersAs development of molecular biomarkers hastens, administrators, clinicians and regulators are working to organize and define biomarkers’ appropriate roles in clinical care—and discussing how to efficiently share the massive amounts of genomic data that will result.
Promising treatment developments in lymphoma immunotherapiesIn this Q&A, a physician and lymphoma expert discusses treatment advances and promising signs for the future.
Novel immunotherapies for leukemia could raise life-threatening syndromeNovel immunotherapy treatments are showing promise for patients with acute lymphoblastic leukemia (ALL), but they can trigger cytokine release syndrome.
Hodgkin lymphoma: First hematologic cancer cured with immunotherapy?Immune checkpoint inhibitors are taking the stage in treating relapsed and refractory Hodgkin lymphoma. Read more.